Olga Panagiotopoulou, Scott T. Chiesa, Dimitrios Tousoulis and Marietta Charakida* Pages 4494 - 4521 ( 28 )
Genetic, experimental and clinical studies have consistently confirmed that inhibition of Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) can result in significant lowering of LDL-C and two fully human PCSK9 monoclonal antibodies have received regulatory approval for use in highrisk patients. Co-administration of PCSK9 with statins has resulted in extremely low LDL-C levels with excellent short-term safety profiles. While results from Phase III clinical trials provided significant evidence about the role of PCSK9 inhibitors in reducing cardiovascular event rates, their impact on mortality remains less clear. PCSK9 inhibitor therapy can be considered for high-risk patients who are likely to experience significant cardiovascular risk reduction.
PCSK9, Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9), alirocumab, evolocumab, LDLcholesterol, monoclonal antibodies.
School of Biomedical Engineering and Imaging Sciences, King's College London, 4th Floor, Lambeth Wing St. Thomas' Hospital, London SE1 7EH, UCL Institute of Cardiovascular Sciences, London, A Cardiology Unit, Kapodistriako University, Athens, School of Biomedical Engineering and Imaging Sciences, King's College London, 4th Floor, Lambeth Wing St. Thomas' Hospital, London SE1 7EH